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Abstract 
A young woman presenting with recurrent 
episodes of uterine bleeding due to an 
extensive uterine arteriovenous malformation 
was treated with two sessions of uterine artery 
embolization. Further bleeding was managed 
with a combination of gonadotropin-releasing 
hormone and depot medroxyprogesterone 
acetate. The patient remains asymptomatic 
with a significant decrease in uterine and 
pelvic vascularity at one year follow-up.  
These drugs may decrease the need for 
repeat embolization. 
1M.S.Ramaiah Medical College, Bangalore, 
India 
 
Introduction  
Uterine arteriovenous malformation is 
rare but causes a serious, life-
threatening hemorrhage. Uterine artery 
embolization is the recommended 
treatment for recurrent episodes of 
bleeding in these cases. There is also 
a place for medical therapy as an 
adjunct to embolization to further 
decrease the vascularity. We present a 
case of extensive uterine 
arteriovenous malformation treated by 
transcatheter embolization followed by 
sequential gonadotropin-releasing 
hormone and depot 
medroxyprogesterone acetate. 
Case report 
A 29 year old G3P1021 presented to 
our emergency department on 
29.10.12 complaining of sudden, 
excessive vaginal bleeding for 2 hours.  
Her recent history revealed the 
following: she had been treated in a 
local hospital 3 ½ weeks previously, 
with a diagnosis of missed abortion at 
12 weeks of gestation, she had 
received tablets for termination of 
pregnancy (details not known).  Not 
responding to this, she had undergone 
a dilatation and curettage on 05.10.12. 
During the procedure, she had 
received two units of blood transfusion 
due to excessive bleeding and a 
hemoglobin of 4.5 gm%.  There were 
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no reports of any histopathological 
examination.  She had persistent 
vaginal bleeding intermittently resulting 
in a pelvic ultrasound on 18.10.12 . 
This showed that the upper half of the 
uterus and the cervix were normal. 
The mid and lower corpus of the 
uterus was grossly enlarged, 
measuring 7.4 x 6.5 x10.0 cm, with a 
complex echotexture and increased 
vascularity with low resistance flow. (PI 
of 0.72-0.62 and RI of 0.52-0.50). The 
anterior wall of the uterus had a 
complex echotexture with multiple 
dilated blood vessels and multiple 
lakes. The impression was of an 
arteriovenous malformation following D 
and C or persistent trophoblastic tissue 
filling the cavity and penetrating the 
myometrium. With a serum β-HCG 
level of 122 mIU/ ml on 19.10.12, she 
was prescribed methotrexate 5 mg 
tablets for 5 days. She was seen by us 
on 29.10.12 with a sudden bout of 
vaginal bleeding.  
Her obstetric history showed an 
uneventful lower segment caesarean 
section 6 years previously and a 
spontaneous abortion at 6 weeks 
about a year ago. There was no 
history of excessive bleeding in these 
two pregnancies. 
Her previous menstrual cycles were 
normal with no history of excessive 
flow. 
At admission, she was pale with a 
pulse of 112/min, BP of 116/76 mm 
Hg. Physical examination was normal. 
There was moderate vaginal bleeding 
with a closed cervical os and a bulky 
uterus and no palpable adnexal mass. 
Her hemoglobin (Hb) was 6 gm% and 
serum β-HCG level was 27 miu/ml. 
The ultrasound scan showed a bulky 
uterus of 11.0 x 4.5 x 5.8 cm with 
fundus and cervix appearing normal.   
Figures 1-4 - Angiography during 
the first session of embolization 
showing the rapid drainage of the 
dye before and a significant 
decrease in flow following 
embolization (figures 1 and 2- right 
pelvic vessels; figures 3 and 4- left 
pelvic vessels) 
 
Figure 1 
 
Figure 2 
A mixed echogenic, vascular lesion in 
the region of the right adnexa and the 
right lateral wall of the uterus 
measuring 5.0 x 5.0 cm was noted. 
Both ovaries were normal. MRI 
suggested a uterine arteriovenous 
malformation (AVM) with a 
heterogenous area in the body of the 
uterus measuring 9.4x4.1x3.5 cm with 
multiple circumferential flow voids with 
marked enhancement on contrast. The 
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fundus of the uterus and cervical 
region appeared normal with normal 
endometrium thickness. She was 
transfused 2 units of packed red cells 
and managed with uterine artery 
embolization on 30.10.12. The initial 
internal iliac angiograms showed 
extensive pelvic A V malformation with 
hypervascularity of the uterine wall and 
early filling of draining veins. The 
feeding arterial branches of uterine 
walls were occluded with polyvinyl 
alcohol (PVA) particles 700 microns 
(Figures 1-4). The patient was stable 
with no further fresh bleeding and was 
discharged the next day. 
 
Figure 3 
 
 
Figure 4 
She presented again 13 days later on 
11.11.2012 with a bout of excessive 
vaginal bleeding. She was pale with a 
pulse of 124 bpm, BP of 130/80 mmHg 
and moderate amount of bleeding. Her 
Hb was 9.8 gm% and serum β-HCG 
was not detected. Ultrasound showed 
residual AVM. Due to the extensive 
nature of the malformation seen during 
embolization, a CT angiogram was 
done which showed extensive pelvic 
AVM with feeders from multiple 
internal iliac branches and ovarian 
arteries. (Figure 5) Demonstration of 
exact feeder arterial anatomy was 
suboptimal because of multiple dilated 
and early filling of draining veins. The 
bleeding reduced and she was 
managed conservatively with 
tranexamic acid.  
 
Figure 5 – CT angiogram showing 
extensive pelvic AVM 
The patient was admitted again 3 
weeks later on 07.12.12 with 
excessive bleeding and giddiness. The 
patient was anxious and pale, with a 
pulse of 88/min, BP of110/70 mmHg 
and minimal bleeding. Hemoglobin 
(Hb) was 11 gm% and serum beta-
HCG was not detected.  On 14.12.12, 
she underwent repeat embolization of 
uterine arteries with PVA particles 
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followed by pelvic arterial embolization 
with cyanoacrylate glue (2cc of 
cyanoacrylate glue, Cook) mixed with 
Lipiodol Ultra-Fluide (Guerbet, 
France). The arteriovenous shunt on 
the right side of pelvis was also 
embolized similarly. Post-embolization 
angiography showed a significant 
reduction of flow in the pelvic vessels. 
(Figures 6,7) The patient was 
discharged after a day of observation. 
 
Figure 6 - Angiography during the 
second session of uterine artery 
embolization. Right pelvic vessels 
pre-embolization 
 
Figure 7- Post embolization 
showing significant obliteration 
 
 
Four days later, on 18.12.12, the 
patient again had excessive vaginal 
bleeding and giddiness. She was 
immediately treated in a nearby 
hospital with intravenous fluids and 
later readmitted in our hospital. On 
examination she was pale, pulse of 
80/min, BP of 110/70 mmHg, with 
minimal bleeding and Hb of 9.5gm%. 
Ultrasound examination showed a 
heterogeneous area of 3.5 x 2.0 cm 
with significant internal vascularity in 
the anterior wall of the uterus. There 
was another similar vascular lesion in 
the right adnexal region of 4.5 x 2.5 cm 
abutting the uterus with the left adnexa 
also showing significant vascularity. 
The impression was a decreased but 
persistent bilateral pelvic and uterine 
arteriovenous malformation. (Figure 8) 
With bleeding reduced but still 
persistent, the patient and her relatives 
were very apprehensive and insistent 
on definitive management with 
hysterectomy. The consequences of 
hysterectomy in the context of 
extensive uterine arteriovenous 
malformation were discussed with 
them. A trial of medical management 
was agreed upon.  She received 
gonadotropin-releasing hormone 
agonist (GnRHa) (Leuprolide depot) 
3.75 mg intramuscularly on 22.12.12 
with the premise that the vascularity 
seen near the endometrium would 
decrease and the endometrium would 
become thin preventing subsequent 
sloughing and bleeding. She was 
discharged with advice for a second 
dose the next month. 
Uterine arteriovenous malformation 4 
 
Proceedings in Obstetrics and Gynecology, 2014;4(1):4 
 
 
Figure 8 – Longitudinal view of 
uterus with mid and lower anterior 
wall showing AVM after two 
sessions of pelvic arterial 
embolization 
Seen a month later, on 21.01.13, she 
was asymptomatic and the ultrasound 
scan showed a very significant 
decrease in vascularity both in the 
uterine myometrium and adnexal 
regions. With the side-effects and cost 
of GnRHa therapy being high, we 
started her on depot 
medroxyprogesterone acetate (DMPA) 
150 mg intramuscular. 
An ultrasound two months later, on 25 
.03.13 showed the uterus with normal 
uterine and pelvic vascularity. (Figures 
9,10). We have continued with 
injections every three months of DMPA 
for a year which has also doubled as a 
reliable contraceptive. The patient has 
remained asymptomatic on regular 
follow-up and a favorable outcome 
with future pregnancies has been 
discussed with her. 
Discussion  
An arteriovenous malformation (AVM) 
is a tangle of blood vessels where 
arteries connect directly to veins 
without an intervening capillary 
network. It is a system of multiple 
feeding arteries, the tangle or nidus, 
and enlarged draining veins, forming a 
high pressure shunt or fistula. The 
vessels which become weak in this 
process can rupture and bleed.  
Figures 9 and 10 – Uterus and right 
adnexa appear normal with normal 
vascularity. 
 
Figure 9 
 
Figure 10 
Uterine arteriovenous malformations 
result from the formation of multiple 
arterio-venous fistulous 
communications within the uterus. 
They can be congenital or acquired. 
Congenital AVMs are usually isolated 
anomalies and arise as a result of a 
defect in embryonic vascular 
differentiation or arrest of 
development. They may extend 
beyond the uterus and can grow as 
pregnancy progresses. Acquired 
AVMs, on the other hand, are usually 
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secondary to previous uterine surgery, 
curettage, carcinoma of the cervix and 
endometrium or trophoblastic disease. 
Pregnancy is thought to play an 
important role in their pathogenesis. It 
is postulated that these malformations 
may arise when venous sinuses 
become incorporated in scars within 
the myometrium after necrosis of the 
chorionic villi. This may also explain 
the association of AVM with 
trophoblastic disease following 
chemotherapy.1 Uterine trauma 
appears to be a common etiological 
factor in all these conditions with the 
potential for development of abnormal 
fistulous communication between 
arteries and veins in the uterine wall. 
Some of these communications may 
develop and persist as an AVM.2 
Clinical features  
The clinical picture of uterine AVM can 
range from being asymptomatic to life-
threatening vaginal bleeding. The 
classical bleeding pattern is 
intermittent and torrential, suggesting 
an arterial hemorrhage. The vaginal 
bleeding can be life threatening in 30% 
of patients requiring transfusion. The 
bleeding presumably occurs when the 
vessels become exposed as they 
erode or abut the endometrium or 
when the endometrium sloughs during 
menstruation.2 They can also manifest 
as torrential bleeding following uterine 
curettage as there is often only a thin 
layer of endometrium overlying the 
malformation, which may be disrupted 
during the procedure.1 The time 
interval when the bleeding occurs after 
the inciting event also appears to be 
variable.3 A history of dilatation and 
curettage and/or uterine surgery has 
been reported 1 month to 7 years 
before the diagnosis with a median of 
19 months. Any patient with 
unexplained vaginal bleeding with a 
history of therapeutic dilatation and 
curettage, abortion, previous uterine 
surgery, endometrial carcinoma or 
gestational trophoblastic disease 
should be suspected of uterine AVM 
regardless of how long back such 
events may have occurred.4 
Diagnosis 
Uterine AVM is usually first diagnosed 
with gray-scale ultrasonography and 
confirmed with color Doppler. While 
radiographic angiography remains the 
gold standard, MRI and CT 
angiography are non-invasive 
modalities which can provide 
additional information to help in 
management. 
The gray-scale sonographic 
appearance of AVM can be variable 
and non-specific. The most common 
finding is the presence of multiple 
tubular anechoic spaces within the 
myometrium, without any mass effect. 
It gives a ‘spongy’ myometrial echo 
texture. Other sonographic features 
can be in the form of a subtle 
heterogeneous myometrium, a focal 
intramural mass mimicking a myoma 
or an endometrial mass resembling an 
endometrial polyp.5 Gynecologic 
vascular abnormalities should be 
considered in women of reproductive 
age with unexplained vaginal bleeding 
and in postmenopausal women in 
whom anechoic structures are 
detected on ultrasound.6 Further 
delineation of AVM is provided by color 
Doppler imaging which shows a tangle 
of vessels with multidirectional high-
velocity flow that produces a color 
mosaic pattern.5 Duplex Doppler 
further reveals the classic features of 
arteriovenous shunting - a picture of a 
fast arterial flow with low resistance: 
high peak systolic velocity, an arterial 
spectral waveform with a high diastolic 
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component, and a pulsatile high-
velocity venous waveform with little 
variation in systolic-diastolic 
velocities.2, 6 
The differential diagnosis of a uterine 
AVM during grey-scale sonography 
includes multilocular ovarian cysts, 
hydrosalpinx, pelvic varicosities, 
gestational trophoblastic disease 
(GTD) and retained products of 
conception. On color Doppler 
ultrasonography, few or no vascular 
signals can be detected either in 
ovarian cysts or hydrosalpinx and 
pelvic varicosities can be differentiated 
by the depiction of prominent 
parametrial vessels with normal 
venous spectral waveforms. But 
retained products of conception and 
GTD appear as an endometrial- based 
mass that show uterine Doppler 
findings similar to an AVM.7 Here a 
serum beta-HCG assay is required 
and the main differentiating point is 
positive β-HCG values. However, it 
should also be kept in mind that 
uterine AVM can coexist with GTD and 
retained products of conception.6,7 
Angiography is considered the 
reference standard for the definitive 
diagnosis of AVM. The classic 
angiographic features consist of a 
complex tangle of vessels supplied by 
enlarged feeding arteries, in 
association with early venous drainage 
during the arterial phase.2 It further 
helps to define the vascular anatomy, 
assess the extent of the vascular 
malformation, and identify the feeding 
vessels. But being an invasive 
procedure this is reserved for patients 
in whom surgical intervention or 
therapeutic transcatheter embolization 
is contemplated. A CT angiography 
may be a good substitute for pelvic 
angiography. A 3D-CT angiography is 
useful for making a differential 
diagnosis and for preoperative 
planning in patients with postabortion 
uterine hemorrhage.8 
MR angiography also allows us to 
confirm the diagnosis of uterine AVM 
non-invasively. It is helpful in 
determining the magnitude of the 
vascular malformation, particularly if 
extrauterine extension is suspected. 
Moreover, additional pelvic disorders 
may be identified and better 
characterized with MRI. Serpiginous 
flow-related signal voids corresponding 
to the myometrial hypervascular areas 
on color Doppler sonography are 
characteristic of uterine AVMs.9 
In our patient, excessive bleeding was 
noticed during the dilatation and 
evacuation procedure necessitating 
blood transfusion. She continued to 
bleed intermittently which led to further 
investigation with ultrasound revealing 
a uterine AVM. With a serum beta-
HCG of 122 mIU/ml, she had received 
methotrexate tablets for ten days 
before coming to us. This is not a 
recommended management option. 
We could find one article expressing 
the usefulness of methotrexate in 
cases of AVM coexisting with retained 
chorionic villi. The authors 
recommended methotrexate therapy or 
a retrial of uterine curettage 
immediately after embolization to 
decrease recanalization of AVM that 
may occur due to rapid recruitment of 
collateral vessels from pelvic arteries 
in these situations.2 We did both an 
MRI and CT angiography in our 
patient. She had a low serum beta-
HCG level which could have been due 
to the presence of retained products of 
conception or more likely an 
occurrence in the normal course of a 
declining beta-HCG level. An MRI 
angiogram was done to confirm AVM, 
especially as it was seen extending to 
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the parametrium and to rule out 
bleeding due to coexistent retained 
products of conception. A CT 
angiography was done after the first 
session of uterine arterial embolization 
when the patient presented with a 
sudden bout of bleeding. The intention 
was to identify the feeder vessels 
which would help in subsequent 
planning but because of the extensive 
nature of the malformation and early 
venous drainage, no specific feeder 
could be identified in the tangle of 
vessels. We found that the uterine 
AVM extended and appeared to 
involve the pelvic vasculature tempting 
us to make a diagnosis of a pelvic 
AVM as well. 
Management  
Following a definitive diagnosis of a 
uterine AVM, further management 
depends on the patient’s 
hemodynamic status, amount of 
bleeding, age, and desire for future 
fertility. Acute management calls for 
stabilizing the hemodynamic status 
and controlling active bleeding. 
Intrauterine tamponade with a Foley’s 
bulb can be a useful temporary 
measure to decrease bleeding. 
Treatment of acquired AVMs requires 
occlusion or resection of all 
arteriovenous communications to 
prevent further life-threatening 
hemorrhage. 
Treatment options are expectant 
management, intra-arterial 
embolization or hysterectomy. Patients 
who are anemic or hemodynamically 
unstable are considered for 
angiography and embolization. This is 
the primary choice when interventional 
radiological expertise is available as it 
is safe and efficacious with fertility 
preservation. Patients with a single 
episode of bleeding who are 
hemodynamically stable can be 
observed, as many of them will remain 
asymptomatic and also because  
traumatic AVMs are reported to 
regress over time.10 If they have 
recurrent bleeding on follow-up, 
embolization is indicated. The decision 
for observation or embolization 
depends on the patient’s clinical status 
rather than on the size of the AVM on 
imaging.6 
Hysterectomy is reserved for patients 
with massive uterine hemorrhage, 
persistent evidence of AVM with 
intractable bleeding, or poor 
compliance with regular follow-up; 
however, surgery may be hazardous in 
the presence of extensive AVM with 
pelvic extension. A cautious approach 
with adequate preparation to deal with 
intra-operative hemorrhage is 
necessary and a more radical 
procedure may be required.11 
Treatment with Transcatheter Arterial 
Embolization 
Percutaneous transcatheter 
embolization is now an accepted, safe 
and highly effective technique for 
controlling obstetric and gynecologic 
hemorrhage. The uterine artery and 
the feeding arteries can be embolized 
with micro particles, coils, glue or 
alcohol, polyvinyl alcohol (PVA), 
cyanoacrylate glue, and stainless steel 
coils while uterine perfusion is 
maintained through collateral supply.3 
The selection of embolic material 
depends on the size and range of the 
AVMs. The number of embolization 
procedures required also varies. A 
single embolization procedure may be 
sufficient for localized AVMs whereas 
multiple procedures are required in 
extensive, complex AVMs. Serial 
embolizations prevent exceeding of 
the contrast-material limits that can 
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happen with lengthy angiographic 
procedures and also reduce the risk of 
excessive embolization, which could 
lead to tissue necrosis or 
complications resulting from post-
thrombosis edema.12 The clinical 
success rate after one to two 
embolization procedures is 93–96%, 
and its complication rate is 4%.3 Most 
of the adverse events after uterine 
artery transcatheter embolization for 
AVM or obstetric hemorrhage are often 
minor when performed by expert 
interventional radiologists. Patients 
may experience pelvic pain and 
nausea for 12–24 hours after the 
procedure, which gradually decreases 
in the next 5–7 days. Major 
complications are rare and include 
uterine necrosis, sepsis, and lethal 
pulmonary embolism.9  
Subsequent pregnancies following 
uterine artery embolization for AVM 
and postpartum hemorrhage are 
reported. Normal intrauterine 
pregnancies occurring after 
embolization with various embolic 
materials like Gelfoam, PVA particles 
and glue prove that an adequate 
collateral blood supply can develop to 
support a full-term pregnancy. There 
are also no reports of major 
complications of pregnancy and labor 
such as severe growth restriction or 
abnormal invasion of the placental bed 
in these patients.13 Thus the 
advantages of uterine artery 
embolization include very high success 
rates, low complication rates, 
avoidance of surgical risks, and 
preservation of fertility with no further 
significant risks in subsequent 
pregnancies.  
In our case the extensive nature of the 
malformation prompted us to plan it as 
a multistage procedure with the use of 
glue in the second session.  
Medical management 
Pharmacological treatment of uterine 
AVMs can be used for patients with 
minimal symptoms and good 
compliance. Estrogens and progestins, 
methylergonovine, danazol, 15-methyl-
prostaglandin F2alpha, oral 
contraceptives and gonadotropin- 
releasing hormone agonist have been 
used though their role is not clear. 
There are no uniform guidelines and 
studies on which to base rational 
treatment in these rare and complex 
cases.  
The mechanism of the beneficial 
effects of drugs on AVMs is not well 
understood. When methylergonovine 
maleate and estrogens were used 
successfully in a patient, it was 
hypothesized that methylergonovine 
maleate induced tetanic myometrial 
contractions to collapse the AVM and 
reduce its blood flow and intravenous 
conjugated estrogens helped by 
covering the hemorrhaging vessels 
with proliferative endometrium.14 
The effect of gonadotropin-releasing 
hormone (GnRH) agonists on uterine 
arteriovenous malformations has not 
been established but holds promise in 
their successful management. It has 
been used alone for six months with 
complete disappearance of the AVM15 
or in conjunction with uterine artery 
embolization, where it was used over 
six months to decrease the size of the 
AVM with follow-up embolization to 
cause its complete disappearance.16 
In our patient, arterial embolization 
was attempted to obliterate the feeding 
vessels of the AVM. When she 
presented with a sudden bout of 
bleeding four days after the second 
session of embolization, GnRH agonist 
was given because of its value in 
decreasing uterine vascularity in both 
Uterine arteriovenous malformation 9 
 
Proceedings in Obstetrics and Gynecology, 2014;4(1):4 
 
myomatous and nonmyomatous 
tissues. We also envisaged that with 
the AVM being so close to the 
endometrium, the drug-induced 
endometrial changes would prevent 
shedding of the endometrium and 
exposing the AVM when given for a 
few months. Though planned as a 
multiple dose treatment, a single dose 
produced sufficient decrease in the 
vascularity of the uterus and pelvis, 
prompting us to follow the GnRH 
agonist therapy with depot 
medroxyprogesterone acetate (DMPA) 
to sustain the avascular status and 
prevent shedding of the endometrium. 
With our patient remaining 
asymptomatic with no side-effects at 
nine months follow-up, GnRH agonist 
therapy followed by DMPA may have 
the potential to be a conservative 
treatment modality for uterine 
arteriovenous malformations in 
hemodynamically stable patients with 
close follow-up.  
Conclusion 
To conclude, our case illustrates an 
acquired uterine AVM. Sonography 
with color Doppler is the primary 
investigation for screening and 
diagnosis. CT angiography or MRI 
angiography can be used to further 
delineate the vascular anatomy and 
rule out pelvic pathology in patients 
with extensive AVMs. They can be 
safely managed with selective 
embolization. Decreased but 
persistent, symptomatic AVMs post-
embolization can be effectively treated 
with GnRH agonist to further decrease 
their vascularity. Combining it with 
DMPA may be an effective, feasible, 
safe, and affordable method in the 
management of complex, life-
threatening uterine AVMs. The 
successful obliteration of the abnormal 
vascular channels in our case gives us 
hope that a single dose of GnRH 
agonist can be used along with long 
term depot medroxyprogesterone 
acetate following uterine artery 
embolization in those women who 
present with repeated bouts of sudden 
vaginal bleeding. These drugs may 
decrease the need for repeat 
embolization. We speculate that in 
places with no facilities for 
interventional radiological expertise, 
treatment with GnRH agonist and 
DMPA to decrease uterine vascularity 
may make a significant difference in 
the management of these difficult 
cases. 
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